company background image
AQST

Aquestive TherapeuticsNasdaqGM:AQST Stock Report

Market Cap

US$228.5m

7D

-13.8%

1Y

-21.6%

Updated

02 Dec, 2021

Data

Company Financials +
AQST fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health0/6
Dividends0/6

AQST Stock Overview

Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally.

Aquestive Therapeutics Competitors

Bausch Health Companies

NYSE:BHC

US$8.3b

Pacira BioSciences

NasdaqGS:PCRX

US$2.4b

Supernus Pharmaceuticals

NasdaqGM:SUPN

US$1.6b

Collegium Pharmaceutical

NasdaqGS:COLL

US$609.0m

Price History & Performance

Summary of all time highs, changes and price drops for Aquestive Therapeutics
Historical stock prices
Current Share PriceUS$5.38
52 Week HighUS$8.06
52 Week LowUS$3.10
Beta3.5
1 Month Change0.37%
3 Month Change18.76%
1 Year Change-21.57%
3 Year Change-38.51%
5 Year Changen/a
Change since IPO-66.48%

Recent News & Updates

Nov 29

Aquestive Therapeutics: Looking To End 2021 On A Bullish Note

Aquestive Therapeutics is moving closer to Libervant’s PDUFA date in December. If approved, Aquestive will finish 2021 on a bullish note that can be sustained into 2022. Aquestive has fought through COVID-19 headwinds and was able to report a strong beat on Q3 with SYMPAZAN continuing to show strong growth over the past 11 consecutive quarters. The company’s AQST-109 epinephrine program reported impressive topline data from a PK study. If approved, AQST-109 could dethrone the EpiPen as the leader in the epinephrine market. I discuss my plans for managing my AQST position ahead of the PDUFA date and potential approval.

Shareholder Returns

AQSTUS PharmaceuticalsUS Market
7D-13.8%-2.7%-3.5%
1Y-21.6%12.4%19.4%

Return vs Industry: AQST underperformed the US Pharmaceuticals industry which returned 12.6% over the past year.

Return vs Market: AQST underperformed the US Market which returned 17.8% over the past year.

Price Volatility

Is AQST's price volatile compared to industry and market?
AQST volatility
AQST Average Weekly Movement8.0%
Pharmaceuticals Industry Average Movement9.3%
Market Average Movement6.1%
10% most volatile stocks in US Market14.9%
10% least volatile stocks in US Market2.4%

Stable Share Price: AQST is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: AQST's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2004187Keith Kendallhttps://www.aquestive.com

Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis.

Aquestive Therapeutics Fundamentals Summary

How do Aquestive Therapeutics's earnings and revenue compare to its market cap?
AQST fundamental statistics
Market CapUS$228.53m
Earnings (TTM)-US$61.96m
Revenue (TTM)US$46.90m

4.6x

P/S Ratio

-3.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
AQST income statement (TTM)
RevenueUS$46.90m
Cost of RevenueUS$14.41m
Gross ProfitUS$32.49m
ExpensesUS$94.45m
Earnings-US$61.96m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-1.54
Gross Margin69.27%
Net Profit Margin-132.11%
Debt/Equity Ratio-66.9%

How did AQST perform over the long term?

See historical performance and comparison

Valuation

Is Aquestive Therapeutics undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: AQST ($5.38) is trading below our estimate of fair value ($154.63)

Significantly Below Fair Value: AQST is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: AQST is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.

PE vs Market: AQST is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AQST's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: AQST has negative assets, so we can't compare its PB Ratio to the US Pharmaceuticals industry average.


Future Growth

How is Aquestive Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

69.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AQST is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).

Earnings vs Market: AQST is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: AQST's is expected to become profitable in the next 3 years.

Revenue vs Market: AQST's revenue (46.1% per year) is forecast to grow faster than the US market (10.1% per year).

High Growth Revenue: AQST's revenue (46.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if AQST's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Aquestive Therapeutics performed over the past 5 years?

-18.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AQST is currently unprofitable.

Growing Profit Margin: AQST is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: AQST is unprofitable, and losses have increased over the past 5 years at a rate of 18.9% per year.

Accelerating Growth: Unable to compare AQST's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AQST is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.2%).


Return on Equity

High ROE: AQST's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Financial Health

How is Aquestive Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: AQST has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: AQST has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: AQST has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: AQST's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AQST has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if AQST has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Aquestive Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate AQST's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AQST's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AQST's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AQST's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AQST's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.6yrs

Average management tenure


CEO

Keith Kendall (63 yo)

7.08yrs

Tenure

US$1,290,418

Compensation

Mr. Keith J. Kendall has been the Chief Executive Officer of MonoSol RX, Inc since December 17, 2014 and also serves as its President, Principal Accounting Officer, Secretary and Treasurer. Mr. Kendall ser...


CEO Compensation Analysis

Compensation vs Market: Keith's total compensation ($USD1.29M) is about average for companies of similar size in the US market ($USD1.13M).

Compensation vs Earnings: Keith's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: AQST's management team is considered experienced (3.6 years average tenure).


Board Members

Experienced Board: AQST's board of directors are considered experienced (3.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19.5%.


Top Shareholders

Company Information

Aquestive Therapeutics, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Aquestive Therapeutics, Inc.
  • Ticker: AQST
  • Exchange: NasdaqGM
  • Founded: 2004
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$228.533m
  • Shares outstanding: 40.16m
  • Website: https://www.aquestive.com

Number of Employees


Location

  • Aquestive Therapeutics, Inc.
  • 30 Technology Drive
  • Warren
  • New Jersey
  • 7059
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/12/02 23:39
End of Day Share Price2021/12/02 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.